http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2015500822-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6851 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6809 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6849 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-454 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate | 2012-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-01-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2015500822-A |
| titleOfInvention | Use of immune complexes targeting CD138 |
| abstract | A method for treating a disease associated with a CD138-expressing target cell, comprising at least one modified target antibody that targets the CD138-expressing cell to a subject in need thereof, particularly a human subject, and at least Administering an immune complex comprising one effector molecule, wherein said modified target antibody forms said immune complex by functionally binding to said effector molecule, preferably said modified At least a portion of the target antibody conferring IgG4 isotype properties, and the immune complex is administered in a multiple dose regimen comprising at least two doses, and the total dose administered during the active treatment cycle is Either the maximum withstand capacity (AMTD) or a part of the AMTD, and at least one of the AMTD and the part is a plurality of times Multiple dose administration regimen that exceeds the dose at which dose limiting toxicity (DLT) occurs when the immunoconjugate is administered as a single dose, including as part of a single dose regimen, and / or during the active treatment cycle A method is provided that exceeds the maximum tolerated dose (MTD) when said immune complex is administered as a single dose comprising as part of [Selection figure] None |
| priorityDate | 2011-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1575.